Five Prime Therapeutics starts dosing FPA144 in Phase 1 clinical trial
Designed to slow down tumor growth, the FPA144 prevents the binding of fibroblast growth factors to FGF receptor 2b (FGFR2b) and is being developed initially as a monotherapy
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to Shanton Pharma for its lead candidate SAP-001, easing the drug’s regulatory paths to approval.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. With this approval, BLINCYTO becomes
The collaboration will focus on the delivery of muscle-protein fusions, and treatment of multiple indications, in the fields of muscular dystrophies, glycogen storage diseases, myopathies and enzyme-deficiency disorders.